Ann: FDAs OTAT Agrees to Primary Endpoint for Back Pain, page-155

OK people with Real Knowledge please clarify for me.

I'm also weary of asking these things, as the idiots who post here, on typically imaginary issues, in an effort to try and devalue MSB hype anything to advance their madness, but I'm a poor simple man, who suffers, I believe, from semi-logical thinking, whilst living on planet Earth, so sometimes I simply get very lost.

We have been advised OTAT have agreed to the basic structure and primary end-point of our proposed PhIII clinical trial for lower-back-pain using "rexlemestrocel-L"

So, does that mean:

OTAT are happy with "rexlemestrocel-L" as a product - they understand it, they approve of it as a potential human therapeutic?  

My non planet Earth friendly logic then suggests, IF OTAT are satisified with "rexlemestrocel-L" as a potential human therapeutic, they [OTAT] would look more than crazy not to green-light Rynocil for kids aGVHD?

Can someone please clarify that my thinking is reasonable given all the knowns and still unknowns?